# BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder

> **NCT03193398** · PHASE2 · COMPLETED · sponsor: **BlackThorn Therapeutics, Inc.** · enrollment: 104 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** BTRX-246040 oral capsule(s)
- **DRUG:** Placebo oral capsule(s)

## Key facts

- **NCT ID:** NCT03193398
- **Lead sponsor:** BlackThorn Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-12
- **Primary completion:** 2018-11-12
- **Final completion:** 2018-12-12
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2021-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03193398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03193398, "BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03193398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*